The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data.
Sriram Sathyanarayanan
Employment or Leadership Position - Merck
Mark Ayers
Employment or Leadership Position - Merck
David Cunningham
Consultant or Advisory Role - Roche (U)
Research Funding - Amgen; AstraZeneca; Roche
Expert Testimony - Amgen (U)
Sabine Tejpar
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Eliza Anne Hawkes
No relevant relationships to disclose
Tae Won Kim
Research Funding - Merck
Tae-You Kim
Research Funding - Merck
Sun Young Kim
Research Funding - Merck
Andrey Loboda
Employment or Leadership Position - Merck
Michael Nebozhyn
Employment or Leadership Position - Merck
Robin Mogg
No relevant relationships to disclose
George Naumov
Employment or Leadership Position - Merck
Andrew Bloecher
Employment or Leadership Position - Merck
Erin Valentine
Employment or Leadership Position - Merck (U)
Holly M. Brown
Employment or Leadership Position - Merck (U)
David J. Watkins
No relevant relationships to disclose
David J. Mauro
Employment or Leadership Position - Merck